Effect of formulation additives on drug transport through size-exclusion membranes

Enika Borbás, Petra Tazsér, Konstantin Tsinman, Oksana Tsinman, K. Takács-Novák, Gergely Völgyi, Balint Sinko, Zsombor Kristof Nagy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this research was to investigate the driving force of membrane transport through size-exclusion membranes and to provide a concentration-based mathematical description of it to evaluate whether it can be an alternative for lipophilic membranes in formulation development of amorphous solid dispersions. Carvedilol, an anti-hypertensive drug, was chosen and formulated using solvent-based electrospinning to overcome the poor water solubility of the drug. Vinylpyrrolidone-vinyl acetate copolymer (PVPVA64) and Soluplus® were used to create two different amorphous solid dispersions of the API. The load-dependent effect of the additives on dissolution and permeation through regenerated cellulose membrane was observed by a side-by-side diffusion cell, μFLUXTM. The solubilizing effect of the polymers was studied by carrying out thermodynamic solubility assays. The supersaturation ratio (SSR, defined as the ratio of dissolved amount of the drug to its thermodynamic solubility measured in exactly the same medium) was found to be the driving force of membrane transport in the case of size-exclusion membranes. Although the transport through lipophilic and size-exclusion membranes are mechanistically different, in both cases the driving force of membrane transport in the presence of polymer additives was found to be the same. This finding may enable the use of size-exclusion membranes as an alternative to lipid membranes in formulation development of amorphous solid dispersions.

Original languageEnglish
JournalMolecular Pharmaceutics
DOIs
Publication statusAccepted/In press - Mar 30 2018

Fingerprint

Membranes
Pharmaceutical Preparations
Solubility
Thermodynamics
Polymers
Membrane Lipids
Cellulose
Antihypertensive Agents
Water
Research

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Effect of formulation additives on drug transport through size-exclusion membranes. / Borbás, Enika; Tazsér, Petra; Tsinman, Konstantin; Tsinman, Oksana; Takács-Novák, K.; Völgyi, Gergely; Sinko, Balint; Nagy, Zsombor Kristof.

In: Molecular Pharmaceutics, 30.03.2018.

Research output: Contribution to journalArticle

Borbás, Enika ; Tazsér, Petra ; Tsinman, Konstantin ; Tsinman, Oksana ; Takács-Novák, K. ; Völgyi, Gergely ; Sinko, Balint ; Nagy, Zsombor Kristof. / Effect of formulation additives on drug transport through size-exclusion membranes. In: Molecular Pharmaceutics. 2018.
@article{75fd2a3cf4b649baa747fab9406e250f,
title = "Effect of formulation additives on drug transport through size-exclusion membranes",
abstract = "The aim of this research was to investigate the driving force of membrane transport through size-exclusion membranes and to provide a concentration-based mathematical description of it to evaluate whether it can be an alternative for lipophilic membranes in formulation development of amorphous solid dispersions. Carvedilol, an anti-hypertensive drug, was chosen and formulated using solvent-based electrospinning to overcome the poor water solubility of the drug. Vinylpyrrolidone-vinyl acetate copolymer (PVPVA64) and Soluplus{\circledR} were used to create two different amorphous solid dispersions of the API. The load-dependent effect of the additives on dissolution and permeation through regenerated cellulose membrane was observed by a side-by-side diffusion cell, μFLUXTM. The solubilizing effect of the polymers was studied by carrying out thermodynamic solubility assays. The supersaturation ratio (SSR, defined as the ratio of dissolved amount of the drug to its thermodynamic solubility measured in exactly the same medium) was found to be the driving force of membrane transport in the case of size-exclusion membranes. Although the transport through lipophilic and size-exclusion membranes are mechanistically different, in both cases the driving force of membrane transport in the presence of polymer additives was found to be the same. This finding may enable the use of size-exclusion membranes as an alternative to lipid membranes in formulation development of amorphous solid dispersions.",
author = "Enika Borb{\'a}s and Petra Tazs{\'e}r and Konstantin Tsinman and Oksana Tsinman and K. Tak{\'a}cs-Nov{\'a}k and Gergely V{\"o}lgyi and Balint Sinko and Nagy, {Zsombor Kristof}",
year = "2018",
month = "3",
day = "30",
doi = "10.1021/acs.molpharmaceut.8b00343",
language = "English",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Effect of formulation additives on drug transport through size-exclusion membranes

AU - Borbás, Enika

AU - Tazsér, Petra

AU - Tsinman, Konstantin

AU - Tsinman, Oksana

AU - Takács-Novák, K.

AU - Völgyi, Gergely

AU - Sinko, Balint

AU - Nagy, Zsombor Kristof

PY - 2018/3/30

Y1 - 2018/3/30

N2 - The aim of this research was to investigate the driving force of membrane transport through size-exclusion membranes and to provide a concentration-based mathematical description of it to evaluate whether it can be an alternative for lipophilic membranes in formulation development of amorphous solid dispersions. Carvedilol, an anti-hypertensive drug, was chosen and formulated using solvent-based electrospinning to overcome the poor water solubility of the drug. Vinylpyrrolidone-vinyl acetate copolymer (PVPVA64) and Soluplus® were used to create two different amorphous solid dispersions of the API. The load-dependent effect of the additives on dissolution and permeation through regenerated cellulose membrane was observed by a side-by-side diffusion cell, μFLUXTM. The solubilizing effect of the polymers was studied by carrying out thermodynamic solubility assays. The supersaturation ratio (SSR, defined as the ratio of dissolved amount of the drug to its thermodynamic solubility measured in exactly the same medium) was found to be the driving force of membrane transport in the case of size-exclusion membranes. Although the transport through lipophilic and size-exclusion membranes are mechanistically different, in both cases the driving force of membrane transport in the presence of polymer additives was found to be the same. This finding may enable the use of size-exclusion membranes as an alternative to lipid membranes in formulation development of amorphous solid dispersions.

AB - The aim of this research was to investigate the driving force of membrane transport through size-exclusion membranes and to provide a concentration-based mathematical description of it to evaluate whether it can be an alternative for lipophilic membranes in formulation development of amorphous solid dispersions. Carvedilol, an anti-hypertensive drug, was chosen and formulated using solvent-based electrospinning to overcome the poor water solubility of the drug. Vinylpyrrolidone-vinyl acetate copolymer (PVPVA64) and Soluplus® were used to create two different amorphous solid dispersions of the API. The load-dependent effect of the additives on dissolution and permeation through regenerated cellulose membrane was observed by a side-by-side diffusion cell, μFLUXTM. The solubilizing effect of the polymers was studied by carrying out thermodynamic solubility assays. The supersaturation ratio (SSR, defined as the ratio of dissolved amount of the drug to its thermodynamic solubility measured in exactly the same medium) was found to be the driving force of membrane transport in the case of size-exclusion membranes. Although the transport through lipophilic and size-exclusion membranes are mechanistically different, in both cases the driving force of membrane transport in the presence of polymer additives was found to be the same. This finding may enable the use of size-exclusion membranes as an alternative to lipid membranes in formulation development of amorphous solid dispersions.

UR - http://www.scopus.com/inward/record.url?scp=85049342440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049342440&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.8b00343

DO - 10.1021/acs.molpharmaceut.8b00343

M3 - Article

AN - SCOPUS:85049342440

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

ER -